Skip to main content
ALIVUS LIFE SCIENCES LIMITED logo

ALIVUS LIFE SCIENCES LIMITED — Investor Relations & Filings

Ticker · ALIVUS ISIN · INE03Q201024 LEI · 335800RYVA1DKP696G32 BSE.NS Manufacturing
Open in API
Filings indexed 352 across all filing types
Latest filing 2023-07-21 Regulatory Filings
Country IN India
Listing BSE.NS ALIVUS

About ALIVUS LIFE SCIENCES LIMITED

https://www.alivus.com

Alivus Life Sciences Limited is a pharmaceutical organization dedicated to the formulation, production, and commercialization of a broad spectrum of healthcare solutions. The company operates across multiple therapeutic categories, including gastroenterology, anti-infectives, pain management, and nutritional supplements. Its product range includes diverse delivery formats such as tablets, capsules, syrups, and injectable medications. Alivus Life Sciences focuses on maintaining rigorous quality control protocols and manufacturing excellence to deliver reliable therapeutic outcomes. The company utilizes a robust distribution infrastructure to supply its pharmaceutical products to healthcare providers and patients, prioritizing the accessibility of essential medicines and the continuous expansion of its therapeutic portfolio.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short communication dated July 21, 2023, addressed to stock exchanges referencing a scrip code and name. It states that the audio recording of the Q1 FY2023-24 Earnings Call has been uploaded to the company's website. The document references SEBI regulations related to disclosure requirements. The content is an announcement about the availability of the earnings call recording, not the transcript or the earnings release itself. The document length is only 1788 characters, which is quite short and consistent with an announcement rather than a full report or transcript. Therefore, this is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about the earnings call recording upload, not the earnings release or call transcript itself.
2023-07-21 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is titled 'Investor Presentation Q1 FY24' and contains detailed financial performance data, segment performance, market mix, and business review for the first quarter of fiscal year 2024. It includes revenue, EBITDA, PAT figures, growth percentages, and operational highlights. The document is addressed to stock exchanges and references compliance with SEBI regulations for disclosure. The length is substantial (15,000 characters), and the content is consistent with a detailed investor presentation rather than a brief earnings release or a full annual report. There is no indication that this is a report publication announcement or a certification. Therefore, the document fits the definition of an Investor Presentation (IP).
2023-07-21 English
Press Release
Interim / Quarterly Report Classification · 100% confidence The document is a press release and Management Discussion & Analysis (MD&A) for the first quarter ended June 30, 2023, as explicitly stated in the text. It contains detailed financial performance data including revenue, EBITDA, PAT, segment performance, and business highlights for Q1 FY24. The document is comprehensive with actual financial figures and analysis, not merely an announcement or a brief summary. It is not a full annual report but a quarterly report with substantive financial data and management commentary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2024
2023-07-21 English
Financial Result Updates
Regulatory Filings
2023-07-21 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges announcing the scheduling of an earnings call for Glenmark Life Sciences Limited for Q1 FY2023-24 financial performance. It includes the date, time, dial-in numbers, and contact details for clarification. The document does not contain any financial data or results itself, but rather serves as an invitation or notification of the upcoming earnings call event. The document length is short (2497 characters), and it primarily announces the earnings call rather than providing the transcript or financial results. Therefore, it is best classified as a Call Transcript announcement or related to earnings call scheduling. However, since it is only an announcement of the earnings call and not the transcript, the closest fitting category is Regulatory Filings (RNS) as a general regulatory announcement about the earnings call event.
2023-07-14 English
Board Meeting — GLENMARK LIFE SCIENCES LIMITED has informed the Exchange about Board Meeting to be held on 21-Jul-2023 to inter-alia consider and approve the Unaudited Financial results of the Compan…
Regulatory Filings
2023-07-13 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.